Professional Documents
Culture Documents
PEPscreen
An Enabling Technology for
Peptide-Based Drug Discovery
biomolecules
PEPscreen
An Enabling Technology for Peptide-Based Drug Discovery
Target Protein
The sequence is known either from gene
sequencing or from protein sequencing.
Functional assay is also well-characterized.
Epitope Sequence
The newly-discovered peptide epitope(s)
constitute leads for peptide-based drug
development.
Optimized Sequence
The optimized sequence represents a drug
candidate, but may not yet be in its final form.
Stabilized Sequence
Final form of peptide drug
Figure 1
General steps in peptide-based drug development. Each color represents a specific amino acid.
wherebiobegins.com/pepscreen
The longer the peptide length, the fewer the number of peptides
to synthesize, and this is especially magnified over longer protein
sequences.
A C D E F G H
I K L M N P Q R S T V W Y
Length = 6
Offset = 2
A C D E F G H
The greater the offset number, the fewer the number of peptides to
synthesize.
The longer the peptide sequence, the more potential for multiple
hits. Hits are defined as peptide sequences that contain all of the
essential residues in the active site or epitope. The attributes for the
different combinations of peptide length and offset numbers are
summarized in Table 1.
I K L M N P Q R S T V W Y
Length = 10
Offset = 2
A C D E F G
A C D E F G H
D E F G H
F G H
H
D E F G H
I K L
F G H
I K L M N
K L M N P Q
I K L
I K L M N
I K L M N P Q
I K L M N P Q R S
K L M N P Q R S T V
M N P Q R S
M N P Q R S T V W Y
P Q R S T V
R S T V W Y
Length = 6
Offset = 4
A C D E F G
F G H
Length = 10
Offset = 4
A C D E F G H
I K L
F G H
K L M N P Q
I K L M N P Q
K L M N P Q R S T V
P Q R S T V W Y
Offset Number
I K L
P Q R S T V W Y
Figure 2
Examples of strategies in selecting sequences for peptide libraries. Residues inside the
dotted box are in the hypothetical active site or epitope. The last peptide sequence
must fulfill all three of the following requirements: (1) it must include the last residue in
the native sequence, (2) it must have more amino acids than the offset number, and (3)
it must have at least 6 residues, the minimum number of residues that can potentially
form an epitope.
Table 1
Summary of the potential effects of the different combinations between peptide length and offset number.
biomolecules
PEPscreen
An Enabling Technology for Peptide-Based Drug Discovery
100
200
400
600
800
1000
Length of Peptides
in the Library
9
12
15
18
9
12
15
18
9
12
15
18
9
12
15
18
9
12
15
18
9
12
15
18
Amino Acid
Offset Number
3
4
5
6
3
4
5
6
3
4
5
6
3
4
5
6
3
4
5
6
3
4
5
6
Table 2
Relationship between the length of the protein, the length of peptides in the library, amino acid offset number and the number of peptide sequences.
Number of Peptides
in Complete Libraries
32
23
18
15
65
48
38
32
132
98
78
65
198
148
118
98
265
198
158
132
331
248
198
165
wherebiobegins.com/pepscreen
I K L M N P Q R S T V W Y A C D E F G H
A C D E F G H
I K
E F G H
H
I K L M N P Q R S T V W Y
I K L M N
I K L M N P Q R
Length = 9
Offset = 3
No. of peptides = 12
L M N P Q R S T V
P Q R S T V W Y A
S T V W Y A C D E
W Y A C D E F G H
C D E F G H
F G H
I K L
I K L M N P
I K L M N P Q R S
M N P Q R S T V W
Q R S T V W Y
A C D E F G H
F G H
I K L M N
I K L M N P Q R S
Length = 12
Offset = 4
No. of peptides = 8
K L M N P Q R S T V W Y
P Q R S T V W Y A C D E
T V W Y A C D E F G H
A C D E F G H
F G H
I
I K L M N
I K L M N P Q R S
K L M N P Q R S T V W Y
A C D E F G H
G H
I K L M N P Q R
I K L M N P Q R S T V W Y
M N P Q R S T V W Y A C D E F
Length = 15
Offset = 5
No. of peptides = 6
S T V W Y A C D E F G H
A C D E F G H
G H
A C D E F G H
H
I K L M N P Q R S T V
I K L M N P Q R S T V W Y A C D E
I K L
I K L M N P Q R
I K L M N P Q R S T V W Y
Length = 18
Offset = 6
No. of peptides = 5
P Q R S T V W Y A C D E F G H
W Y A C D E F G H
F G H
I K L M
I K L M N P Q R S T
I K L M N P Q R S T V W Y
Figure 3
Examples of peptide libraries. Note that this 40-mer
protein is considered a very short protein. Shorter
libraries may be chosen for shorter proteins, while
longer libraries are chosen for longer proteins. Again,
note the relationship between peptide length and the
number of peptides to synthesize. The residues inside
the dotted box constitute the hypothetical epitope.
biomolecules
PEPscreen
An Enabling Technology for Peptide-Based Drug Discovery
Sequence Optimization
Once an epitope is identified the next step is to perform studies to
demonstrate structure and function relationships. These studies are
usually composed of two phases: peptide sequence optimization,
followed by structure stabilization. Ideally, sequence optimization
should be performed by synthesizing all possible sequence
combinations for a given number of residues that constitute an
epitope. Unfortunately, this is impractical because the number
of peptide sequence permutations increase exponentially with
the length of the peptide (Table 3) and it would be impossible to
individually synthesize (at least for now) all the sequences in the
peptide library. Instead, there are four practical strategies that are
used to generate alternative combinatorial libraries.
1. Alanine scanning library (Figure 4A) Alanine is systematically
substituted into each amino acid position in the previously
identified epitope. The purpose of this strategy is to identify
the amino acids in the native sequence that are essential for
activity. Thus, substitution of the essential amino acids with
alanine would be reflected as a significant reduction in activity,
and the degree of reduction in activity is usually taken as a
relative measure of the importance of the particular amino acid
being substituted. Alanine is the amino acid of choice for library
scanning because it is the smallest amino acid that maintains
chirality.
2. Truncation library (Figure 4B) This is a series of peptide
sequences representing the systematic truncation of the
flanking residues to determine the minimum length required
for optimum peptide activity. If the essential amino acids have
already been identified, the direction of truncation can be
selected around these essential amino acids, as opposed to
systematic truncation from both ends of the peptide sequence.
Peptide Length
2
3
4
5
10
15
20
Table 3
Relationship between peptide length and the number of possible sequence permutations for
the 20 naturally occurring amino acids.
wherebiobegins.com/pepscreen
Sequence Stabilization
For some applications, the identification of the epitope and
optimization of the epitope sequence may constitute the end of
the investigation. However, for peptide-based drug development
the optimum peptide sequence usually does not constitute the
final drug candidate. Peptide drugs are usually chemically and
conformationally unstable in circulation and, therefore, their
structures must be stabilized to maintain their potency over time.
The most common strategy to stabilize peptide structures is to
substitute selected amino acids with non-standard amino acids.
Some examples of non-standard amino acids are either homologs of
natural amino acids such as ornithine, homolysine, norleucine, and
norvaline, or the chiral analogs (D-forms) of the naturally-occuring
amino acids (L-forms). Incorporation of these non-standard amino
acids bring about at least three different effects:
A. Alanine Scanning
Library
C. Random
Library
B. Truncation
Library
K L M N P Q
K L M N P Q
K L
A L M N P Q
L M N P Q
K L
X20 X20
K A M N P Q
M N P Q
K L
X20
K L A N P Q
N P Q
K L M
N P Q
X20 X20
K L M A P Q
K L M N P
K L M N
K L M N A Q
K L M N
K L M
K L M N P A
K L M
X20
X20
M N P
L M N
D. Positional Scanning
Library
K L
K L A N P Q
K L M A P Q
K L M N A Q
K L C N P Q
K L M C P Q
K L M N C Q
K L D N P Q
K L M D P Q
K L M N D Q
K L E N P Q
K L M E P Q
K L M N E Q
K L
K L M F
P Q
K L M N F Q
K L G N P Q
K L M G P Q
K L M N G Q
K L H N P Q
K L M H P Q
K L M N H Q
K L
K L M I
K L M N
F N P Q
N P Q
P Q
I Q
K L K N P Q
K L M K P Q
K L M N K Q
K L
K L M L
P Q
K L M N L Q
K L M N P Q
L N P Q
K L M M P Q
K L M N M Q
K L N N P Q
K L M N P Q
K L M N N Q
K L P N P Q
K L M P P Q
K L M N P Q
K L Q N P Q
K L M Q P Q
K L M N Q Q
K L R N P Q
K L M R P Q
K L M N R Q
K L S N P Q
K L M S P Q
K L M N S Q
K L M
T N P Q
K L M T
N P Q
K L M N T
P Q
K L M
V N P Q
K L M V
N P Q
K L M N V
P Q
K L W
M N P Q
K L M W
N P Q
K L M N W
P Q
K L M
Y N P Q
K L M Y
N P Q
K L M N Y
P Q
Q
Q
P Q
L M N P
P Q
Figure 4
Schematic representation of the different strategies in constructing peptide
libraries for sequence optimization. The presumed essential positions are enclosed
in the dotted box.
biomolecules
PEPscreen
Interest panel header
An
Enabling
for Peptide-Based Drug Discovery
Interest
panelTechnology
text
PEPscreen Custom
Peptide Libraries
PEPscreen Service
Specifications
Library Size
Peptide Length
Quantity
Drug discovery
Vaccine development
Protein interaction studies
24 peptide minimum
6 to 20 amino acids
0.5 - 2mg or 2 - 5mg
Dried film at the bottom
of individual tubes
Free amine or acetylated
Free acid or amidated
Any commercially available
non-standard amino acid
Any mixture of commercially
available amino acids
Peptide Form
N-Terminal
C-Termini
Cyclization, phosphorylation,
biotinylation, PEGylation, acylation, etc.
Flc, FITC, Dansyl, Dabcyl, Dabsyl,
TAMRA, Lissamine, etc.
Chemical Modifications
Dye Labeling
eliminates errors
P2
format eliminates cross-contamination and facilitates highthroughput robotic assays. Individual tubes are triple-labeled
for maximum user flexibility
P1
O
Fmoc
N
H
AA2
O
OH
NH AA1
Fmoc
Fmoc
Activation
Deblocking
P1
P2
O
Fmoc
N
H
AA2
H2N AA1
O
AA2
C
Fmoc
NH AA1
Resin
Final deblock
P1
P2
O
H2N
AA2
NH AA1
Resin
P2
Resin
Figure 5
Schematic representation of solid phase
peptide synthesis using Fmoc chemistry.
P1
Cleavage and
deprotection
O
O
H2N
AA2
Repeat steps
for each amino
acid addition
Resin
P1
P2
N
H
Coupling
Fmoc
Resin
NH AA1
OH
Resin
Resin
AA1
Amino Acid 1
AA2
Amino Acid 2
Fmoc
Fmoc protecting
group
Activator
P1
Side-chain
protecting group 1
P2
Side-chain
protecting group 2
wherebiobegins.com/pepscreen
Individual 2D Barcodes
r'BDJMJUBUFTBVUPNBUFEXIPMFQMBUF
TDBOOJOHUPWFSJGZUVCFQPTJUJPOT
r&OBCMFTJEFOUJDBUJPOPGUVCFTXJUIPVU
SFNPWJOHUIFUVCFTGSPNUIFQMBUFSBDL
Figure 6
Packaging and labeling system used for PEPscreen peptides.
biomolecules
PEPscreen
Interest panel header
An
Enabling
for Peptide-Based Drug Discovery
Interest
panelTechnology
text
Mode of operation:
Extraction mode:
Polarity:
Acquisition control:
100
1600.11
Actual MW of
peptide product
(1600.11)
Total ion
count
Accelerating voltage:
Grid voltage:
1.5E+4 Guide wire 0:
Extraction delay time:
Polarity
(Positive mode)
20000 V
94.5%
0.04%
100 nsec
Mass
500 - 6000 Da
15/spectrum
window
1550
3.0 Hz
External - D:\Data\CHEMISTRY
a-Cyano-4-hydroxycinnamic acid
300 Da
14.634
2 nsec
17859
200 mV
0%
150 MHz
Laser control:
Sample positioning:
Search pattern file:
Auto storage mode:
Automated
Automated
D:\Data\CHEMISTRY\BIC and Ca
Save best
50
Min. intensity:
Max. intensity:
Resolution:
Signal-to-noise:
4000
40000
0
20
40
Sample well:
Plate ID:
Serial number:
Instrument name:
Plate type filename:
Lab name:
A12_b
TITAN 96 x 2
1105
PE Biosystems
C:\96 well X2 plate.plt
PE Biosystems
Absolute x-position:
Absolute y-position:
Relative x-position:
Relative y-position:
Shots in spectrum:
Source pressure:
Mirror pressure:
TC2 pressure:
TIS gate width:
TIS flight length:
37428
36892
-37.0153
49.288
15
8.588e-007
0
0.07063
30
940
90
80
70
% Intensity
Linear
Delayed
Positive
Automatic
60
Relative
Intensity
30
20
10
1503.02
Product with
Val deletion
(1503.02)
0
499.0
0
1599.4
2699.8
3800.2
4900.6
Mass (m/z)
Mass-to-charge
ratio
Peptide Number
(93)
6001.0
C-term
[OH]
Order No.
(YYYYY)
Peptide Expected MW
Plate Position
(1600)
Sequence
Plate ID
(A12)
(XXXAAAYYYBBBCCC)
(2VNYUY)
Figure 7
Typical pdf image of MALDI-TOF MS-QC data provided. The more relevant information is highlighted. For a peptide to be deemed
correct, the molecular mass corresponding to the main peak must be within 1 part per thousand relative to the theoretical
molecular mass. Note that since MALDI-TOF generally yields P+H ion, the molecular mass is generally synonymous to the
mass-to-charge ratio (m/z).
N-term
[H]
wherebiobegins.com/pepscreen
Option 21
<90% Dissolved
1. Add 200 ML of 50% HOAc in water to all peptides4
2. Sonicate for 5 minutes
>90% Dissolved
1. Add 100 ML of ACN to
insoluble peptides5
2. Sonicate for 5 minutes
Insoluble
1. Lyophilize insoluble peptides or peptide set6
2. Dissolve in 100 ML DMSO
3. Sonicate for 5 minutes
Peptide Solution
Normalize volume or concentration
with working buffer7
Figure 8
Flow diagram highlighting the
optimized stategies for solubilizing
peptide sets.
11
France
Free Tel: 0800 211 408
Free Fax: 0800 031 052
Tel: (+33) 474 82 28 88
Fax: (+33) 474 95 68 08
Korea
Free Tel: (+82) 80 023 7111
Free Fax: (+82) 80 023 8111
Tel: (+82) 31 329 9000
Fax: (+82) 31 329 9090
Germany
Free Tel: 0800 51 55 000
Free Fax: 0800 64 90 000
Tel: (+49) 89 6513 0
Fax: (+49) 89 6513 1160
Malaysia
Tel: (+60) 3 5635 3321
Fax: (+60) 3 5635 4116
Hungary
Ingyenes telefonszm: 06 80 355 355
Ingyenes fax szm: 06 80 344 344
Tel: (+36) 1 235 9063
Fax: (+36) 1 269 6470
India
Telephone
Bangalore: (+91) 80 6621 9400
New Delhi: (+91) 11 4358 8000
Mumbai: (+91) 22 2570 2364
Hyderabad: (+91) 40 4015 5488
Kolkata: (+91) 33 4013 8003
Fax
Bangalore: (+91) 80 6621 9550
New Delhi: (+91) 11 4358 8001
Mumbai: (+91) 22 4087 2364
Hyderabad: (+91) 40 4015 5488
Kolkata: (+91) 33 4013 8000
Ireland
Free Tel: 1800 200 888
Free Fax: 1800 600 222
Tel: (+353) 402 20370
Fax: (+ 353) 402 20375
Israel
Free Tel: 1 800 70 2222
Tel: (+972) 8 948 4100
Fax: (+972) 8 948 4200
Mexico
Free Tel: 01 800 007 5300
Free Fax: 01 800 712 9920
Tel: (+52) 722 276 1600
Fax: (+52) 722 276 1601
The Netherlands
Free Tel: 0800 022 9088
Free Fax: 0800 022 9089
Tel: (+31) 78 620 5411
Fax: (+31) 78 620 5421
New Zealand
Free Tel: 0800 936 666
Free Fax: 0800 937 777
Tel: (+61) 2 9841 0555
Fax: (+61) 2 9841 0500
Norway
Tel: (+47) 23 17 60 00
Fax: (+47) 23 17 60 10
Poland
Tel: (+48) 61 829 01 00
Fax: (+48) 61 829 01 20
Portugal
Free Tel: 800 202 180
Free Fax: 800 202 178
Tel: (+351) 21 924 2555
Fax: (+351) 21 924 2610
Denmark
Tel: (+45) 43 56 59 00
Fax: (+45) 43 56 59 05
Italy
Free Tel: 800 827 018
Tel: (+39) 02 3341 7310
Fax: (+39) 02 3801 0737
Russia
Tel: (+7) 495 621 5828
Fax: (+7) 495 621 6037
Finland
Tel: (+358) 9 350 9250
Fax: (+358) 9 350 92555
Japan
Tel: (+81) 3 5796 7300
Fax: (+81) 3 5796 7315
Singapore
Tel: (+65) 6779 1200
Fax: (+65) 6779 1822
Enabling Science to
Improve the Quality of Life
2010 Sigma-Aldrich Co. All rights reserved. SIGMA, SAFC, SIGMA-ALDRICH, ALDRICH, FLUKA, and SUPELCO are trademarks belonging to Sigma-Aldrich Co. and its affiliate Sigma-Aldrich
Biotechnology, L.P. Sigma brand products are sold through Sigma-Aldrich, Inc. PEPscreen is a registered trademark of Sigma-Aldrich Biotechnology, L.P. and Sigma-Aldrich Co. TAMRA is a trademark
of Applera Corporation or its subsidiaries in the U.S. and certain other countries. Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich
publications. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see reverse side of the invoice or packing slip.
Slovakia
Tel: (+421) 255 571 562
Fax: (+421) 255 571 564
South Africa
Free Tel: 0800 1100 75
Free Fax: 0800 1100 79
Tel: (+27) 11 979 1188
Fax: (+27) 11 979 1119
Spain
Free Tel: 900 101 376
Free Fax: 900 102 028
Tel: (+34) 91 661 99 77
Fax: (+34) 91 661 96 42
Sweden
Tel: (+46) 8 742 4200
Fax: (+46) 8 742 4243
Switzerland
Free Tel: 0800 80 00 80
Free Fax: 0800 80 00 81
Tel: (+41) 81 755 2828
Fax: (+41) 81 755 2815
United Kingdom
Free Tel: 0800 717 181
Free Fax: 0800 378 785
Tel: (+44) 1747 833 000
Fax: (+44) 1747 833 313
United States
Toll-Free: 800 325 3010
Toll-Free Fax: 800 325 5052
Tel: (+1) 314 771 5765
Fax: (+1) 314 771 5757
Vietnam
Tel: (+84) 3516 2810
Fax: (+84) 6258 4238
Internet
sigma-aldrich.com
World Headquarters
3050 Spruce St.
St. Louis, MO 63103
(314) 771-5765
sigma-aldrich.com
JBU
74228-510155
1110